Aisling Capital Management as of March 31, 2023
Portfolio Holdings for Aisling Capital Management
Aisling Capital Management holds 16 positions in its portfolio as reported in the March 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bridgebio Pharma (BBIO) | 48.4 | $101M | 6.1M | 16.58 | |
| Biomea Fusion (BMEA) | 11.9 | $25M | 799k | 31.01 | |
| Verona Pharma Sponsored Ads (VRNA) | 10.8 | $22M | 1.1M | 20.08 | |
| Syndax Pharmaceuticals (SNDX) | 10.4 | $22M | 1.0M | 21.12 | |
| Monte Rosa Therapeutics (GLUE) | 5.5 | $12M | 1.5M | 7.79 | |
| Elevation Oncology (ELEV) | 2.6 | $5.4M | 2.8M | 1.90 | |
| Reneo Pharmaceuticals (RPHM) | 2.5 | $5.3M | 886k | 5.98 | |
| Nuvation Bio Com Cl A (NUVB) | 2.0 | $4.2M | 2.5M | 1.66 | |
| Aclaris Therapeutics (ACRS) | 1.7 | $3.5M | 435k | 8.09 | |
| Poseida Therapeutics I (PSTX) | 1.5 | $3.2M | 1.0M | 3.08 | |
| Spruce Biosciences (SPRB) | 1.3 | $2.7M | 1.2M | 2.21 | |
| Avrobio Ord (AVRO) | 0.5 | $1.0M | 1.0M | 1.00 | |
| Aeglea Biotherapeutics | 0.2 | $490k | 1.7M | 0.29 | |
| Viracta Therapeutics (VIRX) | 0.2 | $459k | 289k | 1.59 | |
| Atreca Cl A Com (BCEL) | 0.2 | $442k | 388k | 1.14 | |
| Marker Therapeutics Ord | 0.1 | $223k | 314k | 0.71 |
